Three receptors at once
Building on the pattern: an agonist turns a receptor on, a dual agonist turns on two, and a triple agonist turns on three at the same time. In the GLP-1 field, the three targets are the GLP-1, GIP, and glucagon receptors — which is why you’ll sometimes see the shorthand “GGG agonist.” The leading example is retatrutide, an investigational molecule designed to hit all three.
Why add the glucagon receptor
The first two targets are the familiar incretins. The new addition is glucagon, included for a specific reason: glucagon signaling can influence how much energy the body burns and how it handles fat, potentially adding to the blood-sugar and appetite effects of the incretin targets. Stacking all three is the hypothesis behind triple agonists — that reaching the metabolism from several angles at once could push results further than a dual agonist does.
What to keep in mind
This is the frontier of the field, not settled treatment. Triple agonists like retatrutide are still under investigation, so it’s worth being careful about expectations — the mechanism is well-defined, but the full risk-and-benefit picture is still being established through research. If you come across “triple agonist” or “GGG agonist” while reading about what’s next in GLP-1 medications, treat it as a preview of the pipeline rather than an option on the table today. Your clinician is the right source for what’s currently available and appropriate for you.